New treatment approach for non-muscle invasive bladder cancer using special prodrugs
Singlet Oxygen-cleavable Prodrugs for Treating Non-Muscle Invasive Bladder Cancers
This study is testing a new light-activated treatment for non-muscle invasive bladder cancer that aims to kill cancer cells while protecting healthy tissue, and it's designed for patients who have already had some initial treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-10878907 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for non-muscle invasive bladder cancer (NMIBC) that aims to effectively kill cancer cells while minimizing damage to normal bladder tissue. The approach involves using a special type of prodrug that is activated by light in the mitochondria of cancer cells, enhancing the effectiveness of existing therapies. Patients who have undergone initial treatments like transurethral resection will be targeted for this innovative therapy, which seeks to address the significant issue of cancer recurrence. The research builds on previous findings to create a clinically applicable solution for NMIBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-risk non-muscle invasive bladder cancer who have undergone initial treatments.
Not a fit: Patients with muscle-invasive bladder cancer or those who have not been diagnosed with bladder cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer treatment option for patients with non-muscle invasive bladder cancer.
How similar studies have performed: While this approach is innovative, it builds on previous successful concepts in cancer treatment, indicating potential for effectiveness.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: You, Youngjae — State University of New York at Buffalo
- Study coordinator: You, Youngjae
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.